SRNE

Sorrento Therapeutics, Inc. SRNE

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SRNE OZYMF ARUXF QPTFF LBLTF AAGH SIGY SDCCQ FAMDF RASP
6M 677.78 % 0.00 % 21.25 % 0.00 % 0.00 % -98.00 % -53.98 % 0.00 % -77.78 % 0.00 %
YTD 775.00 % 0.00 % 61.67 % 0.00 % 0.00 % 0.00 % -39.37 % -50.00 % -95.00 % 0.00 %
1Y 125.81 % 0.00 % -3.00 % 0.00 % 0.00 % -91.67 % -66.78 % -66.67 % -95.24 % 0.00 %
3Y -55.97 % -43.75 % 24.68 % -82.55 % 0.00 % -86.67 % 667.07 % -99.99 % -95.35 % 53.85 %
5Y -92.13 % -99.15 % -59.58 % -86.76 % -99.73 % -86.67 % 31.72 % -100.00 % -86.67 % -94.29 %
10Y -91.94 % -98.95 % -88.17 % -90.34 % -98.33 % -84.62 % 31.72 % -100.00 % -95.24 % -99.13 %
From the beginning -91.88 % -98.95 % -96.87 % -90.34 % -100.00 % -99.78 % 31.72 % -100.00 % -98.68 % -99.35 %

Dividend

Acrux Limited